$277 Million is the total value of Krensavage Asset Management, LLC's 17 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 15.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Buy | UNITED THERAPEUTICS CORP | $32,562,000 | +11.7% | 275,764 | +0.2% | 11.77% | +12.0% |
| OFIX | Sell | ORTHOFIX INTERNATIONAL NV | $27,366,000 | -0.2% | 639,851 | -1.0% | 9.89% | +0.1% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $26,603,000 | +33.0% | 999,741 | +10.2% | 9.61% | +33.4% |
| IPXL | Buy | IMPAX LABORATORIES INC | $24,463,000 | +16.1% | 1,032,187 | +41.2% | 8.84% | +16.5% |
| Buy | AMGEN INC | $21,024,000 | +9.8% | 126,038 | +0.2% | 7.60% | +10.1% | |
| SCMP | Buy | SUCAMPO PHARMACEUTICALS CL A | $20,335,000 | +13.6% | 1,651,898 | +1.3% | 7.35% | +14.0% |
| HYH | Buy | HALYARD HEALTH INC | $19,974,000 | +6.8% | 576,285 | +0.2% | 7.22% | +7.1% |
| Buy | INDIVIOR PLC | $18,829,000 | +19.2% | 4,736,823 | +0.2% | 6.80% | +19.5% | |
| TEVA | Buy | TEVA PHARMACEUTICAL SP ADR | $18,285,000 | -8.2% | 397,412 | +0.2% | 6.61% | -7.9% |
| MRK | Buy | MERCK & CO INC | $16,103,000 | +8.5% | 258,021 | +0.2% | 5.82% | +8.8% |
| RTIX | Buy | RTI SURGICAL INC | $13,087,000 | -0.1% | 4,181,091 | +14.6% | 4.73% | +0.2% |
| CNMD | Sell | CONMED CORP | $13,051,000 | -16.9% | 325,785 | -1.0% | 4.72% | -16.7% |
| IVC | Buy | INVACARE CORP | $11,652,000 | +6.6% | 1,043,111 | +15.7% | 4.21% | +6.9% |
| Buy | AVIRAGEN THERAPEUTICS INC | $5,210,000 | +37.4% | 2,713,517 | +0.2% | 1.88% | +37.8% | |
| DSCI | Sell | DERMA SCIENCES INC | $4,128,000 | +15.1% | 884,000 | -2.9% | 1.49% | +15.4% |
| DRAD | Buy | DIGIRAD CORP | $2,459,000 | -0.8% | 482,121 | +0.2% | 0.89% | -0.4% |
| JNP | Buy | JUNIPER PHARMACEUTICALS INC | $1,600,000 | -20.7% | 288,294 | +0.2% | 0.58% | -20.5% |
| DEPO | Exit | DEPOMED INC | $0 | – | -217,904 | -100.0% | -1.54% | – |
| AGN | Exit | ALLERGAN PLC | $0 | – | -26,416 | -100.0% | -2.20% | – |
| SHPG | Exit | SHIRE PLC-ADR | $0 | – | -63,166 | -100.0% | -4.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.